KEAP1 and hepatocellular carcinoma: Studies have shown that inhibition of p62-KEAP1-Nrf2 antioxidant signaling pathway can significantly enhance the anti-HCC activity of erastin and sorafenib, indicating that the induction of ferroptosis can promote the anti-HCC targeted sensitization of erastin and sorafenib [53].